Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: The aim of this study was to investigate locus-specific circulating-tumor DNA (ctDNA) methylation for predicting long-term outcomes of locally-advanced rectal cancer (LARC) after resection.
Materials And Methods: In the present study, there were 50 patients without preoperative treatment and 35 patients with preoperative treatment. Methylation analyses for checkpoint with forkhead and ring finger domains (), sex-determining region Y-box transcription factor 11 () and cysteine dioxygenase type 1 () used DNA extracted from plasma ctDNA at the time of resection of the primary tumor with curative-intent surgery.
Results: Highly-methylated in ctDNA was found to be a biomarker of reduced recurrence-free survival (RFS) in LARC. In multivariate analysis, highly methylated was an independent prognostic factor for reduced RFS in the group without preoperative treatment.
Conclusion: The present study demonstrates that elevated ctDNA methylation of the gene is a biomarker for reduced RFS after curative-intent resection of LARC. Patients with high ctDNA methylation of the gene may not be optimal candidates for LARC resection. A prospective study is necessary to further validate ctDNA methylation as a biomarker for RFS of patients with LARC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.17537 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
USP44, ZNF454, and GPRC5B ctDNA Methylation Markers in Breast Cancer: Limited Clinical Relevance for Disease Monitoring and Tumor Characteristics.
Asia Pac J Clin Oncol
September 2025
Department of Surgery, School of Medicine, Daegu Catholic University, Daegu, Republic of Korea.
Purpose: This study aimed to identify breast cancer-specific circulating tumor DNA (ctDNA) methylation markers that correspond to tissue DNA methylation.
Methods: Using The Cancer Genome Atlas (TCGA) database, we selected breast cancer-specific DNA methylation markers. The methylation and expression patterns of candidate genes were analyzed in breast cancer cell lines and tissue samples.
Development and validation of a methylation-specific droplet digital PCR multiplex for lung cancer detection.
Sci Rep
September 2025
Department of Biochemistry and Immunology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Biomarkers are increasingly used in cancer management, including lung cancer. The use of circulating tumour DNA (ctDNA) detection has attracted significant interest as a non-invasive, highly specific, and sensitive strategy. In this study, we developed and validated a methylation-specific droplet digital PCR (ddPCR) multiplex assay with five tumour-specific methylation markers identified by in silico analysis for lung cancer detection across various clinical settings.
View Article and Find Full Text PDFMulti-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.
Front Oncol
August 2025
Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, United States.
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the early detection of esophageal cancer (EC), offering a minimally invasive means to assess tumor-derived genomic and epigenomic alterations. This review synthesizes current data on ctDNA biology, detection technologies, diagnostic performance, and clinical applicability in both esophageal adenocarcinoma and squamous cell carcinoma. We conducted a comprehensive literature review of PubMed-indexed studies on ctDNA in EC, emphasizing recent (January 1, 2019- December 31, 2024) findings, systematic reviews, and meta-analyses.
View Article and Find Full Text PDFBeyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer.
Int J Mol Sci
August 2025
Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with a growing incidence and significant molecular heterogeneity that challenges traditional diagnostic and management paradigms. While histopathological assessment remains the gold standard for diagnosis, emerging liquid biopsy technologies provide promising non-invasive alternatives for tumor detection, molecular profiling, and disease monitoring. This review comprehensively explores the current landscape and clinical utility of liquid biopsy analytes-including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular RNAs, and exosomes-in the context of EC.
View Article and Find Full Text PDFTumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics.
Mol Oncol
August 2025
Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway.
We investigated whether DNA methylation and cell-free DNA (cfDNA) fragmentation patterns can improve circulating tumor DNA (ctDNA) detection in advanced pancreatic cancer. In a cohort of 33 patients, ctDNA detection was performed in a tumor-agnostic fashion using DNA methylation, cfDNA fragment lengths, and 4-mer 5' end motifs. Machine learning models estimating ctDNA levels were built for each individual detection method and their combination.
View Article and Find Full Text PDF